VM26用于恶性血液病的II期研究。

VM26 in malignant hematological diseases. A phase II study.

作者信息

Tirelli U, Carbone A, Franchin G, Galligioni E, Veronesi A, Trovo M G, Volpe R, Tumolo S, Grigoletto E

出版信息

Cancer Chemother Pharmacol. 1982;7(2-3):173-4. doi: 10.1007/BF00254542.

Abstract

From August 1979 to April 1981, 33 consecutive patients with malignant hematological diseases, entered this phase II study. Sixteen patients had NHL, eight CLL, four Myeloma, three HD, one ALL, and one Polycythaemia vera. Two patients were unevaluable because of early death. The median age was 67 years. Eight patients were not pretreated with drugs. Two CR (5+, 20+ weeks) were obtained among NHL patients, whereas five PR were observed among two NHL, one CLL, one Myeloma, and one HD patients, respectively. Toxicity was almost exclusively hematologic and occurred in ten patients, in one of them causing severe myelosuppression. Moreover, severe asthenia, attributable to VM26, was encountered in three patients, in one requiring the suspension of the treatment.

摘要

1979年8月至1981年4月，33例连续性恶性血液病患者进入了这项II期研究。16例为非霍奇金淋巴瘤（NHL），8例为慢性淋巴细胞白血病（CLL），4例为骨髓瘤，3例为霍奇金病（HD），1例为急性淋巴细胞白血病（ALL），1例为真性红细胞增多症。2例患者因早期死亡无法评估。中位年龄为67岁。8例患者未接受过药物预处理。NHL患者中有2例获得完全缓解（CR，分别为5周和20周以上），而在2例NHL、1例CLL、1例骨髓瘤和1例HD患者中分别观察到5例部分缓解（PR）。毒性反应几乎均为血液学毒性，10例患者出现该反应，其中1例导致严重骨髓抑制。此外，3例患者出现了归因于VM26的严重乏力，其中1例需要暂停治疗。